{
    "Trade/Device Name(s)": [
        "ACTOnco",
        "ACTOnco IVD"
    ],
    "Submitter Information": "ACT Genomics Co., LTD",
    "510(k) Number": "K210017",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170058"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZM"
    ],
    "Summary Letter Date": "September 19, 2022",
    "Summary Letter Received Date": "September 26, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6080"
    ],
    "Regulation Name(s)": [
        "Next generation sequencing based tumor profiling test"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Point mutations (SNVs)",
        "Small insertions",
        "Deletions (Indels)",
        "ERBB2 gene amplification",
        "Tumor mutational burden (TMB)"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) tumor tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Thermo Fisher Ion GeneStudio S5 Prime System"
    ],
    "Method(s)/Technology(ies)": [
        "Targeted next generation sequencing",
        "Amplicon-based sequencing",
        "Multiplex PCR"
    ],
    "Methodologies": [
        "Targeted NGS",
        "Amplicon-based NGS",
        "Molecular profiling",
        "Tumor mutational burden calculation"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Reagent",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for ACTOnco IVD targeted next generation sequencing-based tumor profiling assay detecting somatic mutations, gene amplification, and tumor mutational burden in FFPE solid tumor samples.",
    "Indications for Use Summary": "Intended for in vitro diagnostic use to detect genetic alterations (point mutations, insertions, deletions, ERBB2 amplification, and tumor mutational burden) in FFPE tumor tissue from patients with solid malignant neoplasms, providing information for qualified healthcare professionals in accordance with professional guidelines; not prescriptive for any specific therapeutic product.",
    "fda_folder": "Pathology"
}